Professor Louise Emmett presenting ENZAp clinical trial outcomes on the main stage at Melbourne Convention and Exhibition Centre (MCEC). Her conclusion slide describes overall survival with combination of enzalutamide + LuPSMA compared to enzalutamide alone. Improved deterioration-free survival and health-related quality of life indications for pain, fatigue, physical function, and overall health and quality of life.

Great opening plenary at #ANZSNM2025 covering ENZA-p, #LuPSMA under FDA guidelines, total body PET, and new trends in #NET therapy. ☢️✨